{ "@context": "https://orbyd.app/schemas/dossier.v1.json", "ticker": "RCKT", "name": "Rocket Pharmaceuticals, Inc.", "url": "https://orbyd.app/dossiers/RCKT/", "json_url": "https://orbyd.app/dossiers/RCKT.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Broken gene-therapy rebuild bleeding toward its 52-week floor while waiting on binaries: KRESLADI (LAD-I) approved with a Q4 2026 launch and a closed $180M PRV sale fund it, but the re-rate is the undated H2 2026 RP-A501 Danon update — a program with a prior trial death. The 2026-08-05 Q2 print is a cash/launch checkpoint, not the catalyst.", "invalidation_trigger": "A weekly close below $2.53 loses the 52-week basing floor and prints a new low. Secondary breaks: a Danon H2 2026 update with a new safety signal or weak efficacy at the recalibrated 3.8×10¹³ dose, or a dilutive equity raise before the stated Q2 2028 runway.", "catalyst_date": "2026-08-05", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "rare-disease-gene-therapy" ], "tags": [], "sources": [], "notes": [ "Ultra-rare micro-cap ($427M cap, 109.19M sh, $3.91 on 2026-07-10). Single-catalyst binary; size as a probe, never a core. Sector (gene therapy) out of favor since 2022.", "Analyst consensus Buy, ~$9.39 median PT (11 analysts), range $3–$16. Ignore stale ~$44 targets — pre-May-2025 crash artifacts.", "Q2 2026 earnings confirmed 2026-08-05 — treat as a binary print for any fresh entry; blackout window opens ~2026-07-31. Danon data, not this print, is the value driver.", "RP-A501 Danon Phase 2 update guided H2 2026 = the re-rate binary. Prior patient death May 2025 (capillary-leak SAE, novel immune-suppression agent); clinical hold lifted 2025-08-20; reinitiated three-patient cohort at 3.8×10¹³ GC/kg. Watch for a firm date and any new safety signal.", "Price slid $3.91 (2026-07-10) → $3.19 (2026-07-24) on no news; ~21% above the $2.53 52-week floor. Drift, not a coiled base — value-trap stance ahead of the binary.", "Q1 2026 net loss $47.6M (~$190M annualized) vs ~$322.6M pro-forma cash after the $180M PRV sale (closed ~2026-06-12); runway stated into Q2 2028 but dilution risk builds through 2027.", "KRESLADI (LAD-I) FDA accelerated approval March 2026; commercial launch guided Q4 2026 at specialized centers — validates platform, not a near-term revenue engine.", "Ultra-rare micro-cap (~$348M cap, 109.19M sh). Single-catalyst binary; probe sizing only, never a core. Analyst consensus Buy, ~$10 median PT (20 analysts); BofA $10 from $9 (~early June 2026). Ignore stale pre-May-2025 targets." ], "body_markdown": "## Current Thesis\n\nA broken 2021-vintage gene-therapy name that has stopped rebuilding and started bleeding. The May 2025 Danon-trial death gutted the stock; the recovery narrative rests on three legs — a first approved product, a de-risked balance sheet, and a still-pending binary — but the tape is no longer coiling, it is grinding lower. KRESLADI (marnetegragene autotemcel) won FDA accelerated approval for severe LAD-I in March 2026 with commercial launch guided to Q4 2026. A non-dilutive $180M priority-review-voucher sale closed ~2026-06-12, lifting pro-forma cash to ~$322.6M and pushing operational runway into Q2 2028. The genuine value swing remains the reinitiated RP-A501 Danon program, whose Phase 2 update is guided for H2 2026 and is still undated. At $3.19 (2026-07-24) the stock sits in the lower third of a $2.53–$5.45 52-week box, down ~18% in two weeks on no news — a value-trap stance ahead of a binary, not a base ready to break. The 2026-08-05 Q2 print is a cash-and-launch checkpoint, not the catalyst that re-rates the equity.\n\n## Bull Case\n\n- **First commercial gene therapy is real.** KRESLADI won FDA accelerated approval for severe LAD-I in March 2026, with launch guided to Q4 2026 at specialized centers — a validated AAV/lentiviral platform plus an actual product, however small the indication.\n- **Balance sheet extended without touching equity.** Q1 2026 (reported ~2026-05-07) showed $144.4M cash at 3/31; the $180M PRV sale (closed ~2026-06-12) lifts pro-forma cash to ~$322.6M and pushes runway into Q2 2028 — roughly two years of funded operations.\n- **Danon is the re-rate.** RP-A501 reinitiated dosing at a recalibrated 3.8×10¹³ GC/kg with a modified immunomodulatory regimen after the FDA lifted the clinical hold on 2025-08-20 in under three months. The initial three-patient cohort is dosing on track, with an update guided for H2 2026. Clean efficacy at the lower dose is what moves a sub-$350M-cap name.\n- **Cardiac pipeline optionality.** RP-A601 (arrhythmogenic cardiomyopathy) is in FDA alignment on a Phase 2 design; the BAG3 dilated-cardiomyopathy Phase 1 targets first-patient dosing mid-2026 — shots beyond Danon.\n- **Analyst skew still positive.** BofA raised its target to $10 from $9 (~early June 2026, Buy). Consensus is Buy with a ~$10 median across 20 analysts — better than 3x the current $3.19 if the rebuild holds.\n\n## Bear Case\n\n- **Danon carries a death overhang.** The value-driver program already killed a patient — a capillary-leak-syndrome serious adverse event tied to a novel immune-suppression agent, May 2025. Any new safety signal or thin efficacy at the reduced 3.8×10¹³ dose re-breaks the thesis, and the H2 2026 window is undated and easy to slip.\n- **Burn eats the runway before 2028.** Q1 2026 net loss was $47.6M, roughly $190M annualized against ~$322.6M pro-forma cash. A dilutive raise becomes the base case well before the stated Q2 2028 runway, and gene-therapy secondaries price ugly.\n- **The commercial ramp is tiny.** Severe LAD-I is vanishingly rare; a Q4 2026 KRESLADI launch at a handful of centers validates the platform but will not move the P&L near-term.\n- **Sector remains out of favor.** Gene therapy has been de-rated since 2022; a ~$348M micro-cap with no earnings trades on small-cap-biotech risk appetite, which is soft.\n- **The chart is deteriorating.** Price fell from $3.91 (2026-07-10) to $3.19 (2026-07-24) with no headline driving it — a slow drift toward the $2.53 low rather than a coiled base absorbing supply.\n\n## Setup & Price Structure\n\n$3.19 close (2026-07-24), 109.19M shares, ~$348M market cap, inside a 52-week $2.53–$5.45 range. Two weeks ago the stock printed $3.91; it now sits ~21% above the $2.53 low and roughly in the lower third of the box. There is no breakout structure and no momentum — the tape is drifting lower on light news flow while the market waits on the H2 2026 Danon readout. The $2.53 low is the structural floor; the $5.45 high is the ceiling a positive Danon print would need to clear to signal a real re-rate. A below-mid-range grind with a declining price is what a value trap looks like before the catalyst, and the strength required to confirm a trend entry does not exist here. This is a probe-sized binary situation, never a core position.\n\n## Catalyst Calendar (next 30 days)\n\n- **H2 2026 (undated)** — RP-A501 Danon Phase 2 update. The re-rate binary. Outside the 30-day window but the entire reason a probe exists; watch for a firm date announcement.\n- **Mid-2026 (guided)** — BAG3 dilated-cardiomyopathy Phase 1 first-patient dosing; watch for confirmation as a secondary pipeline tell.\n\n## Elapsed catalysts\n\n- **2026-08-05 (confirmed)** — Q2 2026 earnings. Watch cash burn versus the ~$322.6M pro-forma base, runway reaffirmation, KRESLADI launch preparation, and any tightening of Danon timing. Binary print risk for anyone entering fresh; it is a financials checkpoint, not the value catalyst. *(passed 4d ago)*\n\n## What Would Change Our Mind\n\n- **Bull confirmation:** a weekly close back above ~$4.00 that reclaims mid-range on rising volume, or a firmed Danon update date paired with efficacy and no new safety signal at the 3.8×10¹³ dose. Either would turn a drifting probe into a trend setup.\n- **Thesis break (invalidation):** a weekly close below $2.53 loses the 52-week basing floor and prints a new low, at which point the rebuild is a failed setup and fresh entries should stand aside until it bases again. Secondary breaks: a dilutive equity raise before the stated Q2 2028 runway, or a Danon H2 2026 update with a new safety signal or weak efficacy at the recalibrated dose.\n\n## Correlation Notes\n\nRCKT trades as an ultra-rare-disease gene-therapy micro-cap with beta to small-cap biotech (XBI) and to rate-sensitive risk appetite. Sentiment peers include BEAM, NTLA, and KRYS — a clean Danon readout would lift gene-therapy names broadly, a fresh safety event would tar them. Around its own binary the correlation to XBI breaks down: the H2 2026 RP-A501 data dominates the tape and severs the name from index behavior. This is not an index or theme-momentum vehicle; it is a single-catalyst equity that happens to sit inside a gene-therapy basket.\n\n## Sources\n\n- [stockanalysis.com/stocks/rckt](https://stockanalysis.com/stocks/rckt/)\n- [Rocket Q1 2026 results — Businesswire](https://www.businesswire.com/news/home/20260507193942/en/Rocket-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results-and-Highlights-Recent-Progress)\n- [Rocket — FDA lifts clinical hold on RP-A501](https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-fda-has-lifted-clinical-hold)\n- [Rocket $180M PRV sale — StockTitan](https://www.stocktitan.net/news/RCKT/rocket-pharmaceuticals-reports-first-quarter-2026-financial-results-r4lptltd8v97.html)", "first_seen": "2026-07-10", "last_analyzed": "2026-07-26T12:39:23+00:00", "last_synthesized": "2026-07-26", "last_update_source": "watchlist_research", "license": "Content © orbyd. Cite the canonical URL." }